SDCBP and cancer: In other cancers, such as Neurofibromatosis type II, syntenin-1 interacts with Merlin [3], and in hepatocarcinoma, it increases the proliferation and invasion by affecting the levels of EGFR and MMP-2 and activating NFκB [97,98].